Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants

CompletedOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Lymphoma, Mantle-Cell
Trial Locations (9)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100142

Peking University Cancer Hospital, Beijing

130021

The First Hospital of Jilin University, Changchun

200025

Ruijin Hospital, Shanghai Jiao Tong University, Shanghai

200040

Huashan Hospital Fudan University, Shanghai

210029

Jiangsu Province Hospital, Nanjing

300020

Blood Disease Hospital of Chinese Academy of Medical Sciences, Tianjin

410008

Xiangya Hospital Central South University, Changsha

510515

Nanfang Hospital, Guangzhou

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT03053024 - Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants | Biotech Hunter | Biotech Hunter